SEC Form 4 · accession 0001562180-15-000551
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Albert Robichaud
Officer — Chief Scientific Officer
Period of report
Jul 1, 2015
Accepted (ET)
Jul 1, 2015 · 6:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 1, 2015 | S | 9,338 | $72.79 | D | 200,884 | D | |
| Common StockF3 | Jul 1, 2015 | S | 4,905 | $71.43 | D | 195,979 | D | |
| Common StockF4 | Jul 1, 2015 | S | 1,757 | $70.62 | D | 194,222 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $72.04 USD to $72.97 USD. The price reported above reflects the weighted average sale price.
- F3This transaction was executed in multiple trades at prices ranging from $70.91 USD to $71.90 USD. The price reported above reflects the weighted average sale price.
- F4This transaction was executed in multiple trades at prices ranging from $70.04 USD to $70.89 USD. The price reported above reflects the weighted average sale price.